Sign In
Buy EWTX
$43.52
-0.90 (-2.03%)
At Close: Aug 07, 2026
Edgewise Therapeutics, Inc. (EWTX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
03:53am, Thursday, 04'th Dec 2025
Edgewise Therapeutics, Inc. (EWTX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
08:00am, Tuesday, 02'nd Dec 2025
BOULDER, Colo. , Dec. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeuti
Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors
08:00am, Thursday, 20'th Nov 2025
BOULDER, Colo. , Nov. 20, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced the appointment of biotechnology veteran
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
08:00am, Wednesday, 12'th Nov 2025
BOULDER, Colo. , Nov. 12, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeuti
BOULDER, Colo. , Nov. 10, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies an
Edgewise Therapeutics to Participate in Upcoming Investor Conferences
08:00am, Friday, 07'th Nov 2025
BOULDER, Colo. , Nov. 7, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will participate in the
Edgewise Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
08:00am, Thursday, 06'th Nov 2025
– Pivotal GRAND CANYON cohort of sevasemten in Becker expected to read out in Q4 2026; building infrastructure to support potential commercial launch – – MESA open-label extension trial of s
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
08:00am, Monday, 03'rd Nov 2025
BOULDER, Colo. , Nov. 3, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeuti
KLP Kapitalforvaltning AS Has $139,000 Holdings in Edgewise Therapeutics, Inc. $EWTX
03:07am, Wednesday, 22'nd Oct 2025
KLP Kapitalforvaltning AS raised its holdings in Edgewise Therapeutics, Inc. (NASDAQ: EWTX) by 55.9% during the second quarter, according to the company in its most recent Form 13F filing with the Sec
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
04:01pm, Thursday, 02'nd Oct 2025
BOULDER, Colo. , Oct. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutic
BOULDER, Colo. , Oct. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced its participation at the 30th Internatio
Wall Street Analysts Think Edgewise Therapeutics (EWTX) Could Surge 182%: Read This Before Placing a Bet
10:56am, Thursday, 18'th Sep 2025
The mean of analysts' price targets for Edgewise Therapeutics (EWTX) points to an 182% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
07:23pm, Wednesday, 03'rd Sep 2025
BOULDER, Colo. , Sept. 3, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeuti
Wall Street Analysts Believe Edgewise Therapeutics (EWTX) Could Rally 172.96%: Here's is How to Trade
10:55am, Tuesday, 02'nd Sep 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 173% in Edgewise Therapeutics (EWTX). While the effectiveness of this highly sought-after metric is questionabl
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
12:39pm, Sunday, 17'th Aug 2025
NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Edgewise Therapeutics, Inc. (“Edgewise” or the “Company”) (NASDAQ: EWTX). Such inv
